ADXS-503 for Metastatic Squamous and NSCLC - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn if the study drugs (ADXS-503 and Pembrolizumab) are safe to give, and whether they are useful therapies for non-small cell lung cancer.

What is the Condition Being Studied?

Non Small Cell Lung Cancer (NSCLC)

Who Can Participate in the Study?

Adults 18 and older with NSCLC

Age Group

What is Involved?

If you choose to join this study, you will:
-Be in the study for up to 24 months
-Get chemotherapy and immunotherapy
-Give blood samples
-Possibly give a small sample of lung tissue
-Complete regular care with your doctor

Study Details

Full Title
A Phase 1/2, Open-Label Study of ADXS-503 Alone and in Combination with Pembrolizumab in Subjects with Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00101139
NCT: NCT03847519
Phase I/II
Enrollment Status
Open for Enrollment
Contact the Duke Recruitment Innovation Center